Filing exhibits
- 8-K Current report
- 1.1 Underwriting Agreement, Dated As of January 25, 2023, by and Between Jasper Therapeutics, Inc., Credit Suisse Securities (Usa) LLC, William Blair & Company, L.L.C., and Oppenheimer & Co. Inc
- 5.1 Opinion of Paul Hastings LLP
- 99.1 Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
- Download Excel data file
- View Excel data file
Table of Contents